Mobile stroke units (MSU) enable rapid identification and treatment of thrombolytic-eligible patients with acute ischemic stroke (AIS). Recent studies have highlighted the benefit of MSUs over ...
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Xiong and colleagues should ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables. The future of stroke care is likely to be ...
The National Institutes of Health (NIH) halted a treatment arm of Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) in a phase 3 stroke prevention trial after an independent committee flagged safety ...
NEW ORLEANS -- Loberamisal improved functional outcomes after acute ischemic stroke in a placebo-controlled phase III trial, raising its prospects as an investigational neuroprotective therapy. In ...
Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48 hours of stroke symptoms, had better recovery than patients who ...
A single dinged corner can wipe out a $500 sale. When you run an online card shop—on Shopify, eBay, or a fast-growing Whatnot channel—every card is money on the shelf, so storage doubles as risk ...
Hello. Good morning and good afternoon, everybody, and welcome to our investor webinar on the results of the OCEANIC-STROKE Phase III trial directly live from ISC 2026 in New Orleans. So my name is ...
An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary ...
NEW ORLEANS -- A stronger case could be made for intra-arterial (IA) alteplase after successful mechanical thrombectomy based on more randomized data, this time the CHOICE-2 trial from Spain. In acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results